Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

Following the Food and Drug Administration’s polarizing authorization of the Alzheimer’s therapy Aduhelm on Monday, a member of an agency advisory committee that recommended against the drug’s approval has resigned.

Neurologist Joel Perlmutter of Washington University in St. Louis, a member of the FDA’s expert panel for nervous system therapies, told STAT in an email that he had quit the committee on Monday “due to this ruling by the FDA without further discussion with our advisory committee.”

Read the rest…

Member of FDA’s expert panel resigns over controversial Alzheimer’s therapy approval

Leave a Reply

Your email address will not be published. Required fields are marked *

Scroll to top